GOSS, US38341P2011

Chardan sets USD 160.00 target for Gossamer Bio stock

Published on 10/14/2026 at 04:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Chardan's Buy rating names a USD 160.00 target on October 13, 2026. For Gossamer Bio stock, revenue was USD 9.24 million in the second quarter of 2026.

Analyst target and earnings date

Chardan initiated coverage with a Buy rating and a USD 160.00 target on October 13, 2026.
Revenue was USD 9.24 million in the second quarter of 2026, down from USD 11.49 million.
Gossamer Bio is scheduled to report third-quarter results on November 5, 2026.

GOSS, US38341P2011, Illustration mit AI erstellt.

Chardan initiated coverage of Gossamer Bio (ISIN US38341P2011) with a Buy rating and a USD 160.00 price target on October 13, 2026, according to Investing.com. The call centers on potential FDA approval of seralutinib, while the company remains dependent on regulatory and clinical execution.

Three milestones shape the story

On September 11, 2026, Gossamer Bio announced a 1-for-80 reverse stock split, as recorded by StockTitan. On September 23, 2026, the company submitted its first New Drug Application for seralutinib to the FDA, according to Gossamer Bio.

On October 13, 2026, Chardan added the USD 160.00 target and named Gossamer Bio its top small-cap pick for 2027. The target is tied to seralutinib's potential in pulmonary arterial hypertension, but the FDA must still decide whether to accept the application for filing.

What does the filing mean?

The latest reported operating figures show why the regulatory decision matters. Revenue was USD 9.24 million in the second quarter of 2026, down 19.60 percent from USD 11.49 million a year earlier, while net income was USD 16.90 million compared with a GAAP net loss of USD 38.27 million in the prior-year quarter, according to Markets Insider.

Next results date is November 5

Markets Insider lists November 5, 2026, for Gossamer Bio's third-quarter earnings release. As of October 13, 2026, the company had a market capitalization of USD 59.6 million, while its 52-week range was USD 8.99 to USD 309.60. The wide range reflects the effect of the reverse split and the market's sensitivity to clinical and regulatory milestones.

Market value and regulatory risk

Gossamer Bio remains a clinical-stage biotechnology company developing seralutinib for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Chardan's target offers a clear numerical contrast with the company's USD 59.6 million market capitalization, but the investment case depends on FDA review, trial interpretation and access to capital.

Market context: Market report Nasdaq Composite.